Coronary Interventions: The EVEREST Trial Release in High-Risk Acute Coronary Syndromes Treated With Percutaneous Bolus Dose Tirofiban or Abciximab on Tissue-Level Perfusion and Troponin Randomized Comparison of Upstream Tirofiban Versus Downstream High